[
  {
    "ts": null,
    "headline": "Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today",
    "summary": "In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=e27cb977d47e01baa45f1028af439f6efcd9f68825547c52798a968a1501962d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744235105,
      "headline": "Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today",
      "id": 133844490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=e27cb977d47e01baa45f1028af439f6efcd9f68825547c52798a968a1501962d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 3.3% and th",
    "url": "https://finnhub.io/api/news?id=781142ba7881f16e6115ba8ba9dfa3d3b133e90b26e5958f8d70a69fb1fe6b5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744228951,
      "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
      "id": 133844492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 3.3% and th",
      "url": "https://finnhub.io/api/news?id=781142ba7881f16e6115ba8ba9dfa3d3b133e90b26e5958f8d70a69fb1fe6b5b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in",
    "summary": "We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other profitable dividend stocks. Amid growing concerns about economic growth and President Trump’s tariffs, investors have been seeking safer investment options. […]",
    "url": "https://finnhub.io/api/news?id=56f35b2ea28475c7e7c3558a82ce31f025cd7256af40d37c5d91d58201a1f694",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744227473,
      "headline": "Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in",
      "id": 133844493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other profitable dividend stocks. Amid growing concerns about economic growth and President Trump’s tariffs, investors have been seeking safer investment options. […]",
      "url": "https://finnhub.io/api/news?id=56f35b2ea28475c7e7c3558a82ce31f025cd7256af40d37c5d91d58201a1f694"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. Despite this positive development, the company's share price fell by 7% over the last quarter. This decline occurred in the backdrop of a broader market downturn, where major indices, like the S&P 500, experienced a 12% drop due to escalating trade tensions and tariff announcements. BMY’s stock performance, influenced by regional...",
    "url": "https://finnhub.io/api/news?id=a9b3ee22132287b93c2400d8094be4b753adbaa4fad7883c952246f684e46b92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744221017,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy",
      "id": 133844495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. Despite this positive development, the company's share price fell by 7% over the last quarter. This decline occurred in the backdrop of a broader market downturn, where major indices, like the S&P 500, experienced a 12% drop due to escalating trade tensions and tariff announcements. BMY’s stock performance, influenced by regional...",
      "url": "https://finnhub.io/api/news?id=a9b3ee22132287b93c2400d8094be4b753adbaa4fad7883c952246f684e46b92"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More",
    "summary": "PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.",
    "url": "https://finnhub.io/api/news?id=0bc4645b8a990711f6668b739b427d5cbb108e6adfdfd438e7744db23b8e0983",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744220700,
      "headline": "Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More",
      "id": 133844496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.",
      "url": "https://finnhub.io/api/news?id=0bc4645b8a990711f6668b739b427d5cbb108e6adfdfd438e7744db23b8e0983"
    }
  },
  {
    "ts": null,
    "headline": "BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo",
    "summary": "Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.",
    "url": "https://finnhub.io/api/news?id=9a68251f1207939d115c406dae54341904d51a061163b7a0191d09465f61b8fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744220640,
      "headline": "BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo",
      "id": 133844497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.",
      "url": "https://finnhub.io/api/news?id=9a68251f1207939d115c406dae54341904d51a061163b7a0191d09465f61b8fa"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Walmart, Apple, Tesla, Delta, Bristol Myers, Nvidia, Ford, and More",
    "summary": "These Stocks Moved the Most Today: Walmart, Apple, Tesla, Delta, Bristol Myers, Nvidia, Ford, and More",
    "url": "https://finnhub.io/api/news?id=8550abe39e69fece555a40db66d9af3b1871995655dd3bea123dd36301fd6b82",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744216440,
      "headline": "These Stocks Moved the Most Today: Walmart, Apple, Tesla, Delta, Bristol Myers, Nvidia, Ford, and More",
      "id": 134150139,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "These Stocks Moved the Most Today: Walmart, Apple, Tesla, Delta, Bristol Myers, Nvidia, Ford, and More",
      "url": "https://finnhub.io/api/news?id=8550abe39e69fece555a40db66d9af3b1871995655dd3bea123dd36301fd6b82"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Walmart, Pfizer, Apple, Tesla, Delta, Peabody Energy, Nvidia, Ford, and More",
    "summary": "These Stocks Are Moving the Most Today: Walmart, Pfizer, Apple, Tesla, Delta, Peabody Energy, Nvidia, Ford, and More",
    "url": "https://finnhub.io/api/news?id=94607a5e4439c6970c94078ebb32a977bf0c847faa5958925d5f73c8fe070b2f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744192200,
      "headline": "These Stocks Are Moving the Most Today: Walmart, Pfizer, Apple, Tesla, Delta, Peabody Energy, Nvidia, Ford, and More",
      "id": 133828091,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "These Stocks Are Moving the Most Today: Walmart, Pfizer, Apple, Tesla, Delta, Peabody Energy, Nvidia, Ford, and More",
      "url": "https://finnhub.io/api/news?id=94607a5e4439c6970c94078ebb32a977bf0c847faa5958925d5f73c8fe070b2f"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Aren’t a Shelter From the Tariff Storm",
    "summary": "Healthcare Stocks Aren’t a Shelter From the Tariff Storm",
    "url": "https://finnhub.io/api/news?id=ffca3d6117eb4684b7d5277273085053c78d625b36b808a5a724a6c80774b398",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744212120,
      "headline": "Healthcare Stocks Aren’t a Shelter From the Tariff Storm",
      "id": 134149077,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Aren’t a Shelter From the Tariff Storm",
      "url": "https://finnhub.io/api/news?id=ffca3d6117eb4684b7d5277273085053c78d625b36b808a5a724a6c80774b398"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients",
    "summary": "The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date. The approval is based on the Chec",
    "url": "https://finnhub.io/api/news?id=848399db013e0f58c912952da48eef9e0539533b1f44ca875a70d0e1fe194a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744210733,
      "headline": "FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients",
      "id": 133844498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date. The approval is based on the Chec",
      "url": "https://finnhub.io/api/news?id=848399db013e0f58c912952da48eef9e0539533b1f44ca875a70d0e1fe194a2c"
    }
  },
  {
    "ts": null,
    "headline": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
    "summary": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
    "url": "https://finnhub.io/api/news?id=239fef194b45c3e0deed88ea159536c67bcfdddecfa594d190ef5f32a420718c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744199340,
      "headline": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
      "id": 133844748,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
      "url": "https://finnhub.io/api/news?id=239fef194b45c3e0deed88ea159536c67bcfdddecfa594d190ef5f32a420718c"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1",
    "summary": "PRINCETON, N.J. - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients with...",
    "url": "https://finnhub.io/api/news?id=1d8271898dc1a05d96ed0645b28cc59e86f9c81aae175bae2420d7d4dece4419",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744198461,
      "headline": "U.S. Food and Drug Administration Approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1",
      "id": 133833065,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON, N.J. - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients with...",
      "url": "https://finnhub.io/api/news?id=1d8271898dc1a05d96ed0645b28cc59e86f9c81aae175bae2420d7d4dece4419"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’",
    "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O",
    "url": "https://finnhub.io/api/news?id=bbba3c51b8fb3b6449953e17027e686236ad517b530251f4d65aa5f3f54facb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744191647,
      "headline": "Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’",
      "id": 133828471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O",
      "url": "https://finnhub.io/api/news?id=bbba3c51b8fb3b6449953e17027e686236ad517b530251f4d65aa5f3f54facb9"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Downgrades Bristol-Myers Squibb (BMY)",
    "summary": "Goldman Sachs Downgrades Bristol-Myers Squibb (BMY)",
    "url": "https://finnhub.io/api/news?id=4f8ea23e74b621258317c482c87279b6941c9cead3131da8616f9c7bd569504c",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744157014,
      "headline": "Goldman Sachs Downgrades Bristol-Myers Squibb (BMY)",
      "id": 133810839,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4f8ea23e74b621258317c482c87279b6941c9cead3131da8616f9c7bd569504c"
    }
  }
]